Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.3% – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price traded down 7.3% on Tuesday . The stock traded as low as $50.48 and last traded at $49.3790. Approximately 97,929 shares changed hands during trading, a decline of 73% from the average daily volume of 359,392 shares. The stock had previously closed at $53.24.

Wall Street Analysts Forecast Growth

PLSE has been the topic of several recent analyst reports. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Canaccord Genuity Group boosted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pulse Biosciences has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Trading Up 8.6%

The company has a market cap of $3.67 billion, a price-to-earnings ratio of -44.89 and a beta of 1.63. The company has a fifty day moving average price of $39.37 and a two-hundred day moving average price of $28.61.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Sell-side analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,036 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have bought 4,095 shares of company stock worth $199,931. 74.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its holdings in Pulse Biosciences by 2,600.0% during the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock valued at $15,747,000 after purchasing an additional 546,850 shares in the last quarter. Formula Growth Ltd. bought a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $832,000. Panoramic Capital LLC acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $2,719,000. Bank of America Corp DE bought a new stake in Pulse Biosciences in the second quarter valued at $40,115,000. Finally, Jupiter Topco LLC acquired a new position in Pulse Biosciences during the second quarter worth $241,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.